Eisai Co., Ltd. 4523

FDA expands MRK's Welireg label for advanced kidney cancer, adding a third indication as sales climb and the drug gains wider use.

BIIB's growth products now outpace its legacy MS portfolio, with Skyclarys, Zurzuvae and newer drugs driving a shift in revenue mix.

Earlier this month, Eisai and Biogen secured Japanese approval for the at-home LEQEMBI Pen subcutaneous formulation for early Alzheimer’s disease, while Biogen also published Phase 3 VALIANT adolescent subgroup data showing EMPAVELI improved proteinuria and stabilized kidney function in rare complement-mediated kidney disorders. Together, these updates highlight Biogen’s push to make complex therapies more accessible in real-world settings, potentially broadening treatment reach in both...

BioArctic AB (publ)'s (NASDAQ STOCKHOLM: BIOA B) partner Eisai announced today that the subcutaneous autoinjector formulation of Leqembi (known as Leqembi Pen in Japan) has been approved as a new route of administration for the treatment of early Alzheimer's disease.

TARPON SPRINGS, Fla., September 15, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that the Japan Patent Office (JPO) has granted a key patent covering Allarity’s proprietary stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic. The newly granted patent, Japanese Patent No. 7917283, p

Shifting emphasis from symptoms to biomarkers has bolstered sector confidence in emerging CNS therapies.

Biogen (NasdaqGS: BIIB) and Eisai launched LEQEMBI IQLIK, a once-weekly subcutaneous injection for early Alzheimer's disease, now available in the U.S. for initiation and maintenance therapy. The treatment allows at-home dosing for eligible patients using a pre-filled syringe or autoinjector, following a step-up initiation schedule. LEQEMBI IQLIK is described as the first anti-amyloid therapy with an approved subcutaneous initiation option that can be started outside an infusion...

The First and Only Anti-Amyloid Therapy in China that Enables At-Home Administration for Alzheimer’s Disease, a Progressive Neurodegenerative DiseaseTOKYO and CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that the National Medical Products Administration (NMPA) of China has approved the subcutaneous formulation (subcutaneous autoinjector: SC-AI), the anti-amyloid beta (Aβ) protofibril antibody LEQEMBI® (Chinese trademark: 乐意保®

BioArctic AB's (publ) (STO: BIOA B) partner Eisai announced today that Canada's Drug Agency (CDA-AMC) has issued a final recommendation supporting public reimbursement of Leqembi (lecanemab) for eligible patients in Canada with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease (early AD).

An Important Step Forward for Access to LEQEMBI® for Eligible Patients in CanadaTOKYO and CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced today that Canada’s Drug Agency (CDA-AMC) has issued a final recommendation supporting public reimbursement of LEQEMBI® (lecanemab) for eligible patients in Canada living with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease (early AD). The final recommendation follows a r

Eisai Limited ("Eisai") and Biogen Canada Inc. are pleased to receive Canada's Drug Agency (CDA-AMC)'s final positive recommendation supporting public reimbursement for LEQEMBI® (lecanemab), for eligible Canadians living with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease (early AD).

The global indocyanine green (ICG) market was valued at USD 180 million in 2025 and is projected to reach USD 380 million by 2031, growing at a 13.26% CAGR. Growth is driven by fluorescence-guided surgery, minimally invasive procedures, ophthalmic angiography and advanced diagnostics. Solid ICG held a 69% share, while diagnostic procedures led the market. Specialty clinics are forecast to grow fastest at 14.17% CAGR. North America dominated with a 37% share in 2025. Key players include Diagnosti

Eisai (TSE:4523) is back in focus after announcing that once weekly LEQEMBI IQLIK subcutaneous injections for early Alzheimer’s disease are now available in the U.S., offering an at home alternative to intravenous treatment. Over the past 90 days Eisai has recorded a 26.68% share price return, suggesting momentum has picked up again despite a modest year to date share price return of 0.77% and a 1 year total shareholder return of 9.77% compared with deeper 3 and 5 year total shareholder...

Sophus IT Solutions (https://www.linkedin.com/company/sophusitsolutions), an AI native engineering and professional services firm specializing in enterprise AI and geospatial intelligence, today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network.

BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today announced that lecanemab-irmb subcutaneous injection (US brand name: Leqembi Iqlik®), which was approved by the FDA on July 13, now is available in the US for initiation therapy for early Alzheimer's disease[1].Leqembi Iqlik is the first-of-its-kind anti-amyloid treatment that offers at-home dosing for initiation and maintenance (approved in the US).